AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8008712
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of metabolite-to-drug AUC ratios
Trial: 31233326
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n = 25)
Trial: 26035087
Drug: Breathing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing therapy with instructions to raise pCO2
Trial: 26035087
Drug: Breathing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing therapy with instructions to lower pCO2
Trial: 21723534
Drug: Higher treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher treatment expectations
Trial: 21723534
Drug: Pre-treatment OCD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment OCD severity and prior treatment history
Trial: 18807252
Drug: Combined intervention
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intervention (interactive educational meeting plus feedback on medication)
Trial: 16683061
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bupropion
Trial: 16683061
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg sertraline
Trial: 7718029
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ascorbate supplementation (4.5 g/day)
Trial: 2530713
Drug: Selective thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective thromboxane receptor antagonist
Trial: 782997
Drug: Topical pharyngeal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pharyngeal anesthesia with lidocaine
Trial: 28839342
Drug: VBZ 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBZ 80 mg
Trial: 28839342
Drug: VBZ 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBZ 40 mg
Trial: 21511217
Drug: Adjunctive cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive cilostazol (triple group; n = 64)
Trial: 21511217
Drug: High maintenance-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High maintenance-dose clopidogrel (high-MD group; n = 62)
Trial: 17257284
Drug: IFG-lower (5.6-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFG-lower (5.6-6.0 mmol/l)
Trial: 17257284
Drug: IFG-original (6.1-6.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFG-original (6.1-6.9 mmol/l)
Trial: 17257284
Drug: All-IFG (5.6-6.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All-IFG (5.6-6.9 mmol/l)
Trial: 17257284
Drug: Normoglycaemia (<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemia (< 5.6 mmol/l)
Trial: 8274782
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TA) cream 0.1%
Trial: 8274782
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide plus retinoic acid (TARA) cream 0.1% plus 0.025%
Trial: 3116836
Drug: Milk, ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk, ice milk, ice cream, frozen yogurts (without cultures)
Trial: 26556618
Drug: Fentanyl 1
RxNorm normalized name: fentanyl 1.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1 µg/kg (medical patients) or 1.5 µg/kg (surgical patients) administered 10 min before turning
Trial: 26556618
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 10 min before turning
Trial: 20459856
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg aspirin within 1.5 hours after start of thrombolysis
Trial: 20459856
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (antiplatelet therapy after 24 hours)
Trial: 18753120
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg daily for 48 weeks)
Trial: 18753120
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg daily for 48 weeks)
Trial: 18753120
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH; 2 mg for 12 weeks)
Trial: 18753120
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) combined with Rosiglitazone
Trial: 15647414
Drug: Didanosine enteric‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine enteric‐coated 400 mg once daily (reference regimen A)
Trial: 10227447
Drug: Modified FEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FEC regimen (5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 600 mg/m2 for two courses, followed by a modified third course with a dose of 1200 mg/m2) plus G-CSF (filgrastim) at 5 mg/kg.
Trial: 1591822
Drug: Type Ia
RxNorm normalized name: MAGNESIUM ALUMINUM SILICATE TYPE IA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type Ia antiarrhythmic agents (quinidine, procainamide, disopyramide)
Trial: 1591822
Drug: Not receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not receiving type Ia antiarrhythmic agents
Trial: 3918450
Drug: Indomethacin rectal
RxNorm normalized name: indomethacin Rectal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin rectal suppository (100 mg)
Trial: 15985339
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches with counselling
Trial: 12640194
Drug: SQV hard-gelatin
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV hard-gelatin capsule (HGC)/ritonavir (RTV), 1600/100 mg
Trial: 12640194
Drug: SQV soft-gelatin
RxNorm normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SQV soft-gelatin capsule (SGC)/ritonavir (RTV), 1600/100 mg
Trial: 12640194
Drug: SQV soft-gelatin
RxNorm normalized name: ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SQV soft-gelatin capsules (SGCs)
Trial: 12640194
Drug: SQV hard-gelatin
RxNorm normalized name: Hard Gelatin Capsule Shell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV hard-gelatin capsules (HGCs)
Trial: 10759911
Drug: Zolmitriptan, 2.5
RxNorm normalized name: Zolmitriptan, 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan, 2.5 mg
Trial: 10759911
Drug: Sumatriptan, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan, 25 mg
Trial: 11135021
Drug: Sumatriptan, 50
RxNorm normalized name: Naproxen Sodium-Sumatriptan, 500 mg-85 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan, 50 mg
Trial: 28202270
Drug: 25% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% glucose solution
Trial: 28202270
Drug: Fructose solution
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose solution
Trial: 25305000
Drug: M72/AS01 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M72/AS01 (1 or 2 doses)
Trial: 25305000
Drug: Meningitis vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningitis vaccine or EPI vaccines alone
Trial: 1866817
Drug: Chloramphenicol ointment
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ointment and an eye patch for six hours followed by chloramphenicol eyedrops six times a day for six days.
Trial: 1866817
Drug: Chloramphenicol ointment
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloramphenicol ointment and double eye patches for twenty-four hours as the only treatment.
Trial: 27111192
Drug: TC‐3 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC‐3 gel + 200 U OnabotA (Group B)
Trial: 27111192
Drug: TC‐3 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC‐3 gel + 200 U OnabotA + DMSO (Group C)
Trial: 17990225
Drug: Nifurtimox-eflornithine combination
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifurtimox-eflornithine combination therapy (eflornithine 400 mg/kg per day IV every 12 h for 7 days + nifurtimox 15 mg/kg per day orally every 8 h for 10 days)
Trial: 17990225
Drug: Eflornithine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine alone (400 mg/kg per day IV every 6 h for 14 days)
Trial: 12926186
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) with Olea europaea extract, administered preseasonally with a maintenance dose 3.8 times higher than conventional treatments, reaching a maximal dose of 75 BU (45 micrograms Ole e 1).
Trial: 12926186
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SIT treatment).
Trial: 9609132
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day Carbimazole for 12 months (Group 1, n = 23)
Trial: 9609132
Drug: 45 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg/day for the first month, 30 mg/day for the second, and 20 mg/day for the remaining 10 months of Carbimazole (Group 2, n = 34)
Trial: 9815961
Drug: Liposome‐encapsulated muramyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. twice weekly for 8 weeks
Trial: 9815961
Drug: Placebo liposomes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liposomes (lipid equivalent), twice weekly for 8 weeks
Trial: 9815961
Drug: Liposome‐encapsulated muramyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome‐encapsulated muramyl tripeptide phosphatidylethanolamine (L‐MTP‐PE), 2 mg/m2 i.v. once or twice weekly for 8 weeks
Trial: 9815961
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy (CDDP), 70 mg/m2 i.v. every 21 days x 4
Trial: 375153
Drug: promethazine‐A.P.C. combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine‐A.P.C. combination
Trial: 23659338
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 supplementation (500 mg/day)
Trial: 21805296
Drug: Positive control
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive control group (PI without treatment)
Trial: 17223420
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention plus intensive, guideline-driven medical therapy
Trial: 15378098
Drug: Seated exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seated exercise program (three times per week for four cycles of chemotherapy)
Trial: 11469436
Drug: P2 of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2 of 2 msec with d,l-sotalol
Trial: 7616557
Drug: Midazolam (Dormicum)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam (Dormicum) 7.5 mg
Trial: 7616557
Drug: Promethazine (Phenergan)
RxNorm normalized name: promethazine Injection [Phenergan]
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promethazine (Phenergan) 25 mg
Trial: 3283661
Drug: Aspirin 1500
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 1500 mg
Trial: 18070831
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of temocillin (4 g/day)
Trial: 18070831
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily administration of temocillin (2 g every 12 h)
Trial: 15101878
Drug: Telephone-based pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-based pharmaceutical care program
Trial: 15101878
Drug: Routine pharmaceutical
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Routine pharmaceutical care (control)
Trial: 3936089
Drug: Usual daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual daily cigarette consumption
Trial: 31829276
Drug: Real acuTENS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acuTENS treatment for 45 min once a day for five consecutive days
Trial: 31829276
Drug: Sham acuTENS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acuTENS treatment for 45 min once a day for five consecutive days
Trial: 31829276
Drug: Real acuTENS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real acuTENS treatment
Trial: 31829276
Drug: Sham acuTENS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acuTENS treatment
Trial: 24815889
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 27.5 μg
Trial: 22688444
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg (K1)
Trial: 22688444
Drug: Ketamine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 3 mg/kg (K2)
Trial: 16159570
Drug: Huobahuagen Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huobahuagen Tablets (5 tablets po t.i.d.)
Trial: 16159570
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 to 300 mg po q.d.)
Trial: 8826921
Drug: Leuprolide-flutamide androgen
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprolide-flutamide androgen inhibition therapy
Trial: 2147599
Drug: Dichloromethylene bisphosphonate
RxNorm normalized name: (dichloromethylene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered orally for 6 months (1600-2400 mg/day)
Trial: 2147599
Drug: Dichloromethylene bisphosphonate
RxNorm normalized name: (dichloromethylene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by intravenous infusion (500-1000 mg/day)
Trial: 2147599
Drug: Dichloromethylene bisphosphonate
RxNorm normalized name: (dichloromethylene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by intramuscular injection (100-200 mg/day)
Trial: 2147599
Drug: Dichloromethylene bisphosphonate
RxNorm normalized name: (dichloromethylene)bisphosphonic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloromethylene bisphosphonate (C12MBP) administered by mouth (1600-2400 mg/day)
Trial: 6105342
Drug: Propranolol (continuous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (continuous, oral administration, dosage not specified)
Trial: 31856425
Drug: atomoxetine 18
RxNorm normalized name: atomoxetine 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atomoxetine 18 mg daily
Trial: 31856425
Drug: midodrine 5
RxNorm normalized name: midodrine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midodrine 5 mg twice daily
Trial: 31856425
Drug: combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination treatment (atomoxetine and midodrine)
Trial: 31156144
Drug: Kuan-Sin-Yin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuan-Sin-Yin treatment (Group K)
Trial: 31156144
Drug: No Kuan-Sin-Yin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Kuan-Sin-Yin treatment (Group NK)
Trial: 28984747
Drug: 30-day diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-day diazepam treatment
Trial: 28984747
Drug: 10-day diazepam
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day diazepam treatment
Trial: 9608414
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg D-cycloserine
Trial: 9608414
Drug: Higher medication
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher medication dosage or long-term treatment
Trial: 8080299
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with mitomycin C and/or 5-fluorouracil
Trial: 4448416
Drug: Concentrate plus
RxNorm normalized name: ASPIRIN 125 g in 1 L / CAFFEINE 37 g in 1 L ORAL LIQUID [AquaSource Aspirin Liquid Concentrate plus Caffeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate plus heparin
Trial: 31102457
Drug: sildenafil (PDE5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil (PDE5 inhibitor) for 8 weeks in mice
Trial: 31102457
Drug: sildenafil (PDE5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil (PDE5 inhibitor) for 4 weeks in humans
Trial: 25227729
Drug: Concentrated ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ambient coarse PM (CAP) (76.2 ± 51.5 μg/m(3))
Trial: 21442804
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Dexamethasone, Methotrexate, Prednisone)
Trial: 19635128
Drug: web‐based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: web‐based problem solving through the internet (self‐examination therapy) without a coach
Trial: 19635128
Drug: web‐based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: web‐based problem solving through the internet (self‐examination therapy) with the possibility to ask help from a coach on the initiative of the respondent (on demand, by email)
Trial: 19635128
Drug: web‐based problem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: web‐based problem solving through the internet (self‐examination therapy) with weekly scheduled contacts initiated by a coach (once per week, by email)
Trial: 19635128
Drug: weekly scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weekly scheduled contacts initiated by a coach, but no web‐based intervention
Trial: 9240732
Drug: Clodronate 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 300 mg
Trial: 9240732
Drug: Etidronate 300
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etidronate 300 mg
Trial: 9240732
Drug: Clodronate 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 150 mg
Trial: 9240732
Drug: Clodronate 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 600 mg
Trial: 7901952
Drug: Tandospirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone (30 mg)
Trial: 31397127
Drug: Moxibustion combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion combined with umbilical therapy
Trial: 18304907
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 mg/day, adjustable)
Trial: 16996843
Drug: Four IA
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four IA courses at monthly intervals
Trial: 12850861
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg once a week
Trial: 12850861
Drug: Enteric alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric alendronate 70 mg per week
Trial: 10369728
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg/day
Trial: 10369728
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of conjugated estrogens + 1alpha(OH)D3
Trial: 7055528
Drug: Buprenorphine 0.6
RxNorm normalized name: buprenorphine 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.6 mg i.v.
Trial: 30223808
Drug: Community-based care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based care with guardian-administered intramuscular injections
Trial: 17028126
Drug: OAC1W (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC1W (1 week of omeprazole, amoxicillin, and clarithromycin)
Trial: 17028126
Drug: OAC2W (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC2W (2 weeks of omeprazole, amoxicillin, and clarithromycin)